View More Recent Stories

Jul 27, 2016 06:43PM Resverlogix Files 2016 Year-End Disclosure Documents
Jul 21, 2016 02:35PM Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs
Jun 9, 2016 02:15PM Resverlogix Announces Corporate Update Webcast
Jun 2, 2016 08:00AM Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016
May 24, 2016 06:54PM Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA
Apr 18, 2016 08:30AM The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium
Apr 4, 2016 09:25AM Resverlogix Further Strengthens the Board of Directors and Appoints a New Chairman
Mar 1, 2016 01:41PM Resverlogix Announces Corporate Update Webcast
Jan 25, 2016 01:41PM Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal
Nov 11, 2015 10:25AM Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
Nov 9, 2015 07:00AM Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference
Oct 26, 2015 07:00AM Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
Oct 22, 2015 07:00AM Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum
Sep 30, 2015 04:46PM Resverlogix Announces Voting Results
Sep 29, 2015 07:30AM Resverlogix Provides Research and Development Update in New York City
Sep 24, 2015 07:00AM Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases
Sep 10, 2015 07:00AM Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference
Aug 31, 2015 07:00AM Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor
Aug 4, 2015 07:30AM International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"
Jul 21, 2015 09:00AM Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital
Jul 8, 2015 07:00AM Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink
Jun 30, 2015 05:39PM Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement
Jun 22, 2015 07:30AM Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
Jun 17, 2015 07:30AM Resverlogix to Present at the 2015 Bio International Convention
Jun 8, 2015 11:35AM Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA
Jun 1, 2015 07:30AM Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
Apr 27, 2015 07:00AM Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement
Apr 7, 2015 07:30AM Resverlogix Receives Two Patents for RVX-208 in China
Mar 16, 2015 01:30PM Resverlogix Presents at the Prestigious American College of Cardiology 64th Annual Scientific Session & Expo (ACC.15)
View More Recent Stories